PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) today announced that top-line data from its open-label, randomized Phase II clinical trial evaluating its Microcyn® Technology in the treatment of mildly infected diabetic foot ulcers will be presented at DFCon 08 on March 14, 2008. DFCon is one of the world’s premier international diabetic foot conferences held annually.
